share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  08/09 16:36
Moomoo AI 已提取核心訊息
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company has not generated any revenue to date and continues to incur significant operating losses. The net loss for the quarter was approximately $2.8 million, a significant improvement from the net loss of $78.5 million for the same period in the previous year. This reduction in net loss was primarily due to the absence of impairment charges that were recorded in the prior year. Research and development expenses decreased by 41.9% to $709,049, while general and administrative expenses also saw a reduction of 48% to $2,044,929. The company's cash position as of June 30, 2024, was $119,486, a decrease from $3,137,674 at the end of 2023. ZyVersa is focused on the development of drugs for patients with chronic renal or inflammatory diseases and has not yet achieved profitability. The company's future plans include progressing the development of its lead product candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations and potential commercialization.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company has not generated any revenue to date and continues to incur significant operating losses. The net loss for the quarter was approximately $2.8 million, a significant improvement from the net loss of $78.5 million for the same period in the previous year. This reduction in net loss was primarily due to the absence of impairment charges that were recorded in the prior year. Research and development expenses decreased by 41.9% to $709,049, while general and administrative expenses also saw a reduction of 48% to $2,044,929. The company's cash position as of June 30, 2024, was $119,486, a decrease from $3,137,674 at the end of 2023. ZyVersa is focused on the development of drugs for patients with chronic renal or inflammatory diseases and has not yet achieved profitability. The company's future plans include progressing the development of its lead product candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations and potential commercialization.
絲維薩治療公司是一家處於臨床階段的生物製藥公司，公佈了截至2024年6月30日的財務報告。該公司迄今爲止尚未實現任何營業收入並繼續產生巨大的營運虧損。本季度淨虧損約爲280萬美元，相較於去年同期的淨虧損7,850萬美元，取得了顯著改善。淨虧損的降低主要是由於前一年記錄的減值費用不再存在。研發費用減少了41.9％至709,049美元，而總務及行政費用也減少了48％至2,044,929美元。截至2024年6月30日，該公司的現金儲備爲119,486美元，較2023年底的3,137,674美元有所減少。絲維薩致力於爲患有慢性腎臟或炎症性疾病的患者開發藥物，目前尚未實現盈利。該公司未來的計劃包括推進其主導產品VAR 200和IC 100的開發，並尋求額外的資金支持持續營運和潛在的商業化。
絲維薩治療公司是一家處於臨床階段的生物製藥公司，公佈了截至2024年6月30日的財務報告。該公司迄今爲止尚未實現任何營業收入並繼續產生巨大的營運虧損。本季度淨虧損約爲280萬美元，相較於去年同期的淨虧損7,850萬美元，取得了顯著改善。淨虧損的降低主要是由於前一年記錄的減值費用不再存在。研發費用減少了41.9％至709,049美元，而總務及行政費用也減少了48％至2,044,929美元。截至2024年6月30日，該公司的現金儲備爲119,486美元，較2023年底的3,137,674美元有所減少。絲維薩致力於爲患有慢性腎臟或炎症性疾病的患者開發藥物，目前尚未實現盈利。該公司未來的計劃包括推進其主導產品VAR 200和IC 100的開發，並尋求額外的資金支持持續營運和潛在的商業化。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息